NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rocket Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $21.62 -0.04 (-0.18 %) (As of 01/26/2020 04:00 PM ET) Add Compare Today's Range$21.41Now: $21.62▼$22.3450-Day Range$20.76MA: $22.58▼$24.7352-Week Range$10.76Now: $21.62▼$27.59Volume289,170 shsAverage Volume340,867 shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/ABeta2.84 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT Previous Symbol CUSIPN/A CIK1281895 Webhttp://www.rocketpharma.com/ Phone646-440-9100Debt Debt-to-Equity Ratio0.20 Current Ratio11.07 Quick Ratio11.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book4.84Profitability EPS (Most Recent Fiscal Year)($1.89) Net Income$-74,520,000.00 Net MarginsN/A Return on Equity-39.80% Return on Assets-30.75%Miscellaneous Employees33 Outstanding Shares50,380,000Market Cap$1.09 billion Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive RCKT News and Ratings via Email Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RCKT Rates by TradingView Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals Inc (NASDAQ:RCKT) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.11. View Rocket Pharmaceuticals' Earnings History. When is Rocket Pharmaceuticals' next earnings date? Rocket Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Rocket Pharmaceuticals. What price target have analysts set for RCKT? 8 equities research analysts have issued 12-month target prices for Rocket Pharmaceuticals' shares. Their forecasts range from $27.00 to $42.00. On average, they expect Rocket Pharmaceuticals' stock price to reach $35.80 in the next twelve months. This suggests a possible upside of 65.6% from the stock's current price. View Analyst Price Targets for Rocket Pharmaceuticals. What is the consensus analysts' recommendation for Rocket Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rocket Pharmaceuticals. Has Rocket Pharmaceuticals been receiving favorable news coverage? News articles about RCKT stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Rocket Pharmaceuticals. Who are some of Rocket Pharmaceuticals' key competitors? Some companies that are related to Rocket Pharmaceuticals include BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), FibroGen (FGEN), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Taro Pharmaceutical Industries (TARO) and Myokardia (MYOK). What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Pfizer (PFE), Home Depot (HD), Cisco Systems (CSCO), Fate Therapeutics (FATE), MEI Pharma (MEIP), NVIDIA (NVDA) and Viking Therapeutics (VKTX). Who are Rocket Pharmaceuticals' key executives? Rocket Pharmaceuticals' management team includes the folowing people: Mr. Gaurav Shah, CEO, Pres & Director (Age 44)Mr. John C. Militello, Controller (Age 46)Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, COO & Head of Devel. (Age 39)Dr. Claudine Prowse Ph.D., Sr. VP of Corp. Strategy & IROMr. Jonathan Schwartz, Chief Medical Officer (Age 55) How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $21.62. How big of a company is Rocket Pharmaceuticals? Rocket Pharmaceuticals has a market capitalization of $1.09 billion. The biotechnology company earns $-74,520,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe.View Additional Information About Rocket Pharmaceuticals. What is Rocket Pharmaceuticals' official website? The official website for Rocket Pharmaceuticals is http://www.rocketpharma.com/. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected] MarketBeat Community Rating for Rocket Pharmaceuticals (NASDAQ RCKT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 282 (Vote Outperform)Underperform Votes: 201 (Vote Underperform)Total Votes: 483MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote "Outperform" if you believe RCKT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: What is a balanced fund?
